ClinicalTrials.gg
CompletedNCT00880620APEX-PDUpdated Oct 29, 2019Results posted

A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease

A Phase 3 interventional study of Placebo and IPX066 95 mg LD in Parkinson's Disease, sponsored by Impax Laboratories, LLC. Completed at 60 sites in 7 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2019-10-29.

Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
381
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · Amneal Pharmaceuticals, Inc..

Enrollment
5th of 14
381 · median 77
Started
2009
with 1 other
Phase 3
7 of 14
none open now
Registered
5th of 14
by date

Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., this one is the 5th largest by enrollment, is one of 2 that started in 2009, is one of 7 in phase 3, and was the 5th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

This study examines the efficacy of three doses of IPX066 as compared to placebo in Parkinson's disease.

Read the detailed description

A randomized, double-blind, placebo-controlled, fixed-dose, parallel-arm study of three doses of IPX066 versus placebo.

Total of 427 subjects were screened and 381 were randomized and received one of the four treatment groups (1) placebo (N=92), (2) IPX066 145 mg LD (N=87) (3) IPX066 245 mg LD (N=104) (4) IPX066 390 mg LD (N=98) three times a day.

Study duration is approximately 30 weeks for each subject including 4 weeks of titration (up to 3 weeks of dose escalation and I week of stabilization for safe escalation to the allocated dose), and 26 weeks of maintenance.

During the titration phase:

The following dose strengths were used to titrate up to the final three strengths that were assigned to the three IPX066 treatment arms.

IPX066 95 mg LD capsule containing 95 mg LD and 23.75 mg CD. IPX066 145 mg LD capsule containing 145 mg LD and 36.25 mg CD. IPX066 195 mg LD capsule containing 195 mg LD and 48.75 mg CD. IPX066 245 mg LD capsule containing 245 mg LD and 61.25 mg CD.

During the maintenance phase:

IPX066 145 mg LD treatment arm received 145 mg LD and 36.25 mg CD. IPX066 245 mg LD treatment arm received 245 mg LD and 61.25 mg CD. IPX066 390 mg LD treatment arm received 390 mg LD and 97.50 mg CD.

Primary efficacy outcome measure was change from baseline in the sum of UPDRS Part II and Part III scores at the end of study or last value reported if subject discontinued prematurely.

Summary of Change From Baseline to End of Study in Mean Parkinson's Disease Questionnaire-39 (PDQ-39) Score.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Parkinson's disease
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and willing to voluntarily sign an form (ICF) and Health Insurance Portability and Accountability Act (HIPAA) authorization or local equivalent if applicable.
  2. Diagnosed with idiopathic PD.
  3. LD-naïve: defined as subjects not exposed to LD or catechol-O-methyl transferase inhibitors for more than 30 days and the exposure is not within 4 weeks prior to study enrollment.
  4. If currently taking anticholinergic therapy, amantadine, or a monoamine oxidase type B (MAO-B) inhibitor, maintains a stable regimen for at least 4 weeks prior to Baseline, and agrees to maintain the stable regimen throughout study participation.
  5. Agrees to use a medically acceptable method of throughout the study and for 1 month after completing the study.
  6. Able and willing to comply with the protocol, including availability for all scheduled clinic visits and telephone calls.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding.
  2. Diagnosed with atypical Parkinsonism or any known secondary parkinsonian syndrome.
  3. Prior functional neurosurgical treatment for PD or if such procedures are anticipated during study participation.
  4. Use of nonselective MAO inhibitors.
  5. Use of dopamine agonists within 30 days prior to Screening.
  6. Unable to tolerate a placebo regimen, in the Investigator's opinion.
  7. Treatment of psychosis with any antipsychotic.
  8. History of seizure or epilepsy.
  9. Active or prior medical condition or prior surgical procedure that would interfere with LD absorption.
  10. History of narrow-angle glaucoma.
  11. Subjects with a history of malignant melanoma.
  12. History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome.
  13. Received any medications during the 30 days prior to Screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
381 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    One Placebo capsule was given TID for the first 21 days. Two placebo capsules were given TID on days 22 till end of study (week 30).

    Drug: Placebo

  • Experimental
    IPX066 145 mg LD

    One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-21. One IPX066 145 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).

    Drug: Placebo · Drug: IPX066 95 mg LD · Drug: IPX066 145 mg LD

  • Experimental
    IPX066 245 mg LD

    One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. One IPX066 245 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).

    Drug: Placebo · Drug: IPX066 95 mg LD · Drug: IPX066 145 mg LD · Drug: IPX066 195 mg LD · Drug: IPX066 245 mg LD

  • Experimental
    IPX066 390 mg LD

    One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. Two IPX066 195 mg LD capsules were given TID on days 22 till end of study (week 30).

    Drug: IPX066 95 mg LD · Drug: IPX066 145 mg LD · Drug: IPX066 195 mg LD · Drug: IPX066 245 mg LD

Interventions

  • DrugPlacebo

    Placebo

  • DrugIPX066 95 mg LD

    IPX066 capsule containing 95 mg LD/23.75 mg CD

    Also known as: CD-LD ER 95 mg

  • DrugIPX066 145 mg LD

    IPX066 capsule containing 145 mg LD/36.25 mg CD

    Also known as: CD-LD ER 145 mg

  • DrugIPX066 195 mg LD

    IPX066 capsule containing 195 mg LD/48.75 mg CD

    Also known as: CD-LD ER 195 mg

  • DrugIPX066 245 mg LD

    IPX066 capsule containing 245 mg LD/61.25 mg CD

    Also known as: CD-LD ER 245 mg

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III at Week 30

    Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) + UPDRS Part III (Motor Examination) at Week 30 (End of Study). Unified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome. Subscales II and III were summed: Part I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25

    Time frame: Week 30

Secondary outcomes

  1. Summary of Change From Baseline to End of Study in Mean Parkinson's Disease Questionnaire-39 (PDQ-39) Score

    Change from Baseline in Parkinson's disease Questionnaire 39 (PDQ-39) at Weeks 4, 9, 16, 23 and 30 or early discontinuation was collected. The PDQ-39 is a self-reported questionnaire consisting of 39 questions regarding the subjects mobility and the responses consist of "Never" (better in outcome), (value 0), "Occasionally" (value 1), "Sometimes" (value 2), , "Often" (value 3), and "Always" (value 4), (worse in outcome). The minimum possible score is "0" and the maximum is "156". The outcome measure calculated was the change from baseline to end of study in mean PDQ-39 score. Negative values indicate a better result.

    Time frame: Baseline and Week 30 (or End of Study)

07

Results

Posted Feb 22, 2016

Participant flow

First patient enrolled: 4/13/2009 Last patient out 10/05/2010

Participant flow — Overall Study
MilestonePlaceboIPX066 145 mg LDIPX066 245 mg LDIPX066 390 mg LD
Started928710498
Week 488799486
Week 980738878
Week 1674738774
Week 2371728574
Completed71728374
Not completed21152124
Withdrew: Adverse event451515
Withdrew: Death0010
Withdrew: Lack of efficacy12401
Withdrew: Lost to follow-up0110
Withdrew: Protocol violation0102
Withdrew: Withdrawal by subject4313
Withdrew: Noncompliance0011
Withdrew: Other1122

Outcome measures

PrimaryChange From Baseline in the Sum of UPDRS Part II + UPDRS Part III at Week 30

Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) + UPDRS Part III (Motor Examination) at Week 30 (End of Study). Unified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome. Subscales II and III were summed: Part I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25

Time frame:
Week 30
Reported as:
Mean · units on a scale
Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III at Week 30
units on a scalePlaceboIPX066 145mg LDIPX066 245 mg LDIPX066 390 mg LD
Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III at Week 30-0.6 ± 10.37-11.7 ± 10.97-12.9 ± 11.42-14.9 ± 11.85
SecondarySummary of Change From Baseline to End of Study in Mean Parkinson's Disease Questionnaire-39 (PDQ-39) Score

Change from Baseline in Parkinson's disease Questionnaire 39 (PDQ-39) at Weeks 4, 9, 16, 23 and 30 or early discontinuation was collected. The PDQ-39 is a self-reported questionnaire consisting of 39 questions regarding the subjects mobility and the responses consist of "Never" (better in outcome), (value 0), "Occasionally" (value 1), "Sometimes" (value 2), , "Often" (value 3), and "Always" (value 4), (worse in outcome). The minimum possible score is "0" and the maximum is "156". The outcome measure calculated was the change from baseline to end of study in mean PDQ-39 score. Negative values indicate a better result.

Time frame:
Baseline and Week 30 (or End of Study)
Reported as:
Mean · score on a scale
Summary of Change From Baseline to End of Study in Mean Parkinson's Disease Questionnaire-39 (PDQ-39) Score
score on a scaleIPX066 145 mg LDIPX066 245 mg LDIPX066 390 mg LDPlacebo
Summary of Change From Baseline to End of Study in Mean Parkinson's Disease Questionnaire-39 (PDQ-39) Score-4.4 ± 12.18-3.8 ± 12.16-6.0 ± 12.300.6 ± 11.10

Adverse events

Collected over 1 year, 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—3/92 (3.3%)26/92 (28.3%)
IPX066 145 mg LD—4/87 (4.6%)27/87 (31%)
IPX066 245 mg LD—5/104 (4.8%)47/104 (45.2%)
IPX066 390 mg LD—2/98 (2%)48/98 (49%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPlaceboIPX066 145 mg LDIPX066 245 mg LDIPX066 390 mg LD
Acute myocardial infarctionCardiac disorders0/921/870/1040/98
Coronary artery diseaseCardiac disorders0/921/870/1040/98
Myocardial infarctionCardiac disorders0/921/870/1040/98
Escherichia urinary tract infectionInfections and infestations0/921/870/1040/98
UrosepsisInfections and infestations1/920/870/1040/98
Cerebrovascular accidentNervous system disorders1/920/870/1040/98
ProstatectomySurgical and medical procedures1/920/870/1040/98
Urinary tract infectionInfections and infestations0/920/870/1041/98
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/920/870/1041/98
EmphysemaRespiratory, thoracic and mediastinal disorders0/920/870/1041/98
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboIPX066 145 mg LDIPX066 245 mg LDIPX066 390 mg LD
NauseaGastrointestinal disorders8/9212/8720/10420/98
DizzinessNervous system disorders5/928/8720/10412/98
HeadacheNervous system disorders10/926/8713/10417/98
InsomniaPsychiatric disorders3/922/879/1046/98
Dry MouthGastrointestinal disorders1/923/872/1047/98
Abnormal dreamsPsychiatric disorders0/922/876/1045/98
ConstipationGastrointestinal disorders1/922/876/1042/98
DepressionPsychiatric disorders5/921/872/1042/98
VomitingGastrointestinal disorders3/922/872/1045/98
DyskinesiaNervous system disorders0/922/874/1045/98

Baseline characteristics

Baseline Analysis Population is all treated

Age, Continuous
Age, Continuous(years)PlaceboIPX066 145 mg LDIPX066 245 mg LDIPX066 390 mg LDTotal
Mean65.4 ± 9.4363.8 ± 9.8165.2 ± 9.7364.8 ± 9.3264.8 ± 9.55
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboIPX066 145 mg LDIPX066 245 mg LDIPX066 390 mg LDTotal
Female40404544169
Male52475954212
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboIPX066 145 mg LDIPX066 245 mg LDIPX066 390 mg LDTotal
Hispanic or Latino357419
Not Hispanic or Latino87789189345
Unknown or Not Reported246517
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboIPX066 145 mg LDIPX066 245 mg LDIPX066 390 mg LDTotal
Asian10012
Black or African American00202
White908710296375
Other10012
Region of Enrollment
Region of Enrollment(participants)PlaceboIPX066 145 mg LDIPX066 245 mg LDIPX066 390 mg LDTotal
Canada1099937
Latvia11002
Romania1313151455
United States30293738134
Ukraine28293226115
Lithuania748827
Estonia323311
Age at Parkinson's disease onset
Age at Parkinson's disease onset(years)PlaceboIPX066 145 mg LDIPX066 245 mg LDIPX066 390 mg LDTotal
Mean63.7 ± 9.4861.7 ± 10.7163.6 ± 10.4363.0 ± 9.3863.0 ± 10.00
Duration of Parkinson's disease
Duration of Parkinson's disease(years)PlaceboIPX066 145 mg LDIPX066 245 mg LDIPX066 390 mg LDTotal
Mean1.8 ± 2.012.3 ± 3.081.8 ± 1.852.0 ± 2.332.0 ± 2.34
UPDRS Parts II and III Score
UPDRS Parts II and III Score(units on a scale)PlaceboIPX066 145 mg LDIPX066 245 mg LDIPX066 390 mg LDTotal
Mean36.3 ± 11.8936.1 ± 13.5638.1 ± 15.6336.3 ± 13.0436.7 ± 13.63

2 further baseline measures are reported on the registry.

08

Study locations

60 sites
  • University of Alabama at Birmingham, Dept. of Neurology
    Birmingham, Alabama 35233, United States
  • HOPE Research Institute, LLC
    Phoenix, Arizona 85050, United States
  • Collaborative NeuroScience Network, Inc.
    Garden Grove, California 92845, United States
  • Coastal Neurological Medical Group
    La Jolla, California 92037, United States
  • Coordinated Clinical Research
    La Jolla, California 92037, United States
  • The Parkinson's Institute
    Sunnyvale, California 94085, United States
  • Yale Neurology Clinics, Temple Medical Center
    New Haven, Connecticut 06510, United States
  • Bradenton Research Center, Inc.
    Bradenton, Florida 34205, United States
  • Sunrise Clinical Research, Inc.
    Hollywood, Florida 23021, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Charlotte Neurological Services
    Port Charlotte, Florida 33952, United States
  • Suncoast Neuroscience Associates, Inc.
    Saint Petersburg, Florida 33713, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Idaho Elks Rehabilitation Hospital
    Boise, Idaho 83702, United States
  • Rush University Medical Center, Dept. of Neurological Sciences
    Chicago, Illinois 60612, United States
  • Landon Center on Aging, Dept. of Neurology, Parkinson's Disease Center
    Kansas City, Kansas 66160-7314, United States
  • Boston University School of Medicine
    Boston, Massachusetts 02118, United States
  • Quest Research Institute
    Bingham Farms, Michigan 48025, United States
  • Struthers Parkinson's Center
    Golden Valley, Minnesota 55427, United States
  • UMDNJ Robert Wood Johnson Medical Center, Department of Neurology
    New Brunswick, New Jersey 08901, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Columbia University
    New York, New York 10032, United States
  • State University of New York Upstate Medical University, Dept. of Neurology
    Syracuse, New York 13210, United States
  • Duke University Medical Center Movement Disorders Center
    Durham, North Carolina 27705, United States
  • University of Toledo
    Toledo, Ohio 43614, United States
  • Baylor College of Medicine, Parkinson's Disease Center
    Houston, Texas 77030, United States
  • Wisconsin Institute for Neurologic and Sleep Disorders
    Milwaukee, Wisconsin 53233, United States
  • Movement Disorders Clinic, Glenrose Rehabilitation Hospital
    Edmonton, Alberta T5G 0B7, Canada
  • Saint Boniface Clinic
    Winnipeg, Manitoba R3J2H7, Canada
  • London Health Science Center
    London, Ontario N6A 5A5, Canada
  • Parkinson's and Neurodegenerative Disorders Clinic
    Ottawa, Ontario K1G 4G3, Canada
  • Ottawa Hospital Civic Site
    Ottawa, Ontario K1Y 4E9, Canada
  • Toronto Western Hospital
    Toronto, Ontario M5T 2S8, Canada
  • University of Sherbrooke
    Sherbrooke, Quebec J1H 5N4, Canada
  • Memory and Motor Skills Clinic
    Quebec, G1R 3X5, Canada
  • East Tallinn Central Hospital
    Tallinn, 10138, Estonia
  • West Tallin Central Hopsital
    Tallinn, 10617, Estonia
  • P.Stradina university hospital
    Riga, 1002, Latvia
  • Gailezers hospital
    Riga, Latvia
  • Kaunas Medical University Hospital
    Kaunas, LT-50009, Lithuania
  • Siauliai Regional Hospital
    Siauliai, LT- 76231, Lithuania
  • Vilnius University Emergency Hospital
    Vilnius, LT-04130, Lithuania
  • Vilnius University Centre of Gerontology and Rehabilitation
    Vilnius, LT-08420, Lithuania
  • Vilnius University Hospital Santariskiu klinikos
    Vilnius, LT-08661, Lithuania
  • Psychiatry and Neurology Hospital, Neurology Department
    Brasov, 500123, Romania
  • Colentina Clinical Hospital Bucharest, II Neurology Department
    Bucharest, 020125, Romania
  • County Emergency Clinical Hospital Cluj-Napoca, I Neurology Clinic
    Cluj Napoca, 400012, Romania
  • CFR Clinical Hospital Constanta
    Constanta, 900123, Romania
  • Clinical Rehabilitation Hospital Iasi, Neurology Department
    Iasi, Romania
  • County Clinical Emergency Hospital, Targu Mures, II Neurology Department,
    Targu Mures, 540136, Romania
  • County Clinical Emergency Hospital Timisoara
    Timisoara, 300736, Romania
  • Neurology department of Regional hospital named after Mechnikov
    Dnepropetrovsk, 49005, Ukraine
  • Department of Psychiatry and Medical Psychology of Donetsk National Medical University
    Donetsk, 83037, Ukraine
  • Department of Neurological Diseases and Medical Genetic of Donetsk National Medical University
    Donetsk, 83099, Ukraine
  • 1st neurology department of Central Clinical Hospital of Ukrzaliznytsya
    Kharkiv, Kharkiv, Ukraine
  • Institute of Gerontology Parkinson's Disease Center
    Kiev, 04114, Ukraine
  • Neurology department of Lviv regional clinical hospital
    Lviv, 79010, Ukraine
  • Neurology department of Medical Dental Academy based on Poltava regional hospital
    Poltava, 36000, Ukraine
  • Neurology department of Vinnitsa Medical University
    Vinnitsa, 21018, Ukraine
  • Neurology department, Zaporozhye State Medical University
    Zaporozhye, 69035, Ukraine
09

References and documents

Publications

  • Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, Hsu A, O'Connell M, Kell S, Gupta S; APEX-PD Investigators. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord. 2014 Feb;20(2):142-8. doi: 10.1016/j.parkreldis.2013.08.017. Epub 2013 Sep 5. PubMed 24055014 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Oct 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 5 years 4 months after primary completion. A results delay was requested in Sep 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2009
First posted
Apr 14, 2009
Start
Apr 2009
Primary completionActual
Oct 2010
CompletionActual
Nov 2010
Results delay requested
Sep 27, 2013
Results first posted
Feb 22, 2016
Last update
Oct 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00880620
Responsible party
Sponsor
First posted
Apr 14, 2009
Start date
Apr 2009
Primary completion
Oct 2010
Completion
Nov 2010
Results posted
Feb 22, 2016
Last update
Oct 29, 2019

Study contacts

Impax Study Director
study director · Impax Laboratories, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion